Tocilizumab, an activity blocker for Interleukin-6 (IL-6), a critical inflammatory/immune-mediated cytokine in macrophage activation, was used as a salvage treatment in a few cases of hyperhemolysis syndrome in sickle cell disease [3]. Here, IL6 is linked to sickle cell disease.